Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CPRX
Previous Symbol
CUSIPN/A
Phone305-420-3200
Debt
Debt-to-Equity RatioN/A
Current Ratio18.06
Quick Ratio18.06
Price-To-Earnings
Trailing P/E Ratio-11.62
Forward P/E Ratio-8.13
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.79 per share
Price / Book3.09
Profitability
EPS (Most Recent Fiscal Year)($0.21)
Net Income$-18,410,000.00
Net MarginsN/A
Return on Equity-34.06%
Return on Assets-32.49%
Miscellaneous
Employees21
Outstanding Shares102,740,000
Market Cap$245.55 million
OptionableOptionable
Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions
What is Catalyst Pharmaceuticals' stock symbol?
Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."
How were Catalyst Pharmaceuticals' earnings last quarter?
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.08) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.08). View Catalyst Pharmaceuticals' Earnings History.
When is Catalyst Pharmaceuticals' next earnings date?
What price target have analysts set for CPRX?
4 equities research analysts have issued 12-month price targets for Catalyst Pharmaceuticals' stock. Their forecasts range from $5.00 to $8.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $6.25 in the next year. This suggests a possible upside of 155.1% from the stock's current price. View Analyst Price Targets for Catalyst Pharmaceuticals.
What is the consensus analysts' recommendation for Catalyst Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Pharmaceuticals.
What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?
Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Our price target of $6/share is based on an equally weighted composite of: (a) $6.62/ share, as a 35x multiple of taxed and diluted 2024 GAAP EPS of $0.57 discounted back to 2018 at 20%; and (b) an NPV of discounted cash flows between 2018-2024 of $4.46/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of Firdapse to secure regulatory approval in the US; and (2) failure of Firdapse to achieve peak commercial revenue estimates in our model due to market size, penetration rates, and/or pricing." (11/9/2018)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $8 PT on CPRX. This morning BMO, Catalyst hosted an earnings call and reported 3Q18 expenses of $8.2M and cash & investments of $66.7M. Our model projects sufficient cash to fund operations through the anticipated Firdapse launch in 2019. Questions on the call centered on potential near-term Firdapse approval (PDUFA goal date Nov. 28), as well as go-to-market strategy, including patient access and pricing. Additionally, the company now plans to expand to the Canadian market (just announced)." (11/8/2018)
- 3. According to Zacks Investment Research, "Catalyst only has one candidate, Firdapse, in late stage development. All the other candidates are in early stages of development. Thus, the successful development and commercialization of drug candidates is highly uncertain and remains a concern. The company’s share price movement shows that the stock has underperformed the industry year to date. However, Catalyst resubmitted the new drug application (NDA) of Firdapse for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in March 2018. The FDA accepted the NDA and granted Priority Review to the same in May 2018. The FDA has set an action date of Nov 28, 2018. A potential approval will boost the growth prospects. The company is also actively engaged in pre-commercialization activities for a potential launch of the drug. Meanwhile, the company is also developing Firdapse for additional indications. Loss esytimates have narrowed ahead of Q3 earnings release." (10/10/2018)
Has Catalyst Pharmaceuticals been receiving favorable news coverage?
Media coverage about CPRX stock has trended somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
Are investors shorting Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 2,520,504 shares, an increase of 41.4% from the October 31st total of 1,782,314 shares. Based on an average daily volume of 1,912,888 shares, the short-interest ratio is presently 1.3 days. Approximately 2.7% of the shares of the company are sold short. View Catalyst Pharmaceuticals' Current Options Chain.
Who are some of Catalyst Pharmaceuticals' key competitors?
Some companies that are related to Catalyst Pharmaceuticals include Rhythm Pharmaceuticals (RYTM), Homology Medicines (FIXX), Puma Biotechnology (PBYI), Revance Therapeutics (RVNC), Intra-Cellular Therapies (ITCI), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Crinetics Pharmaceuticals (CRNX), Dicerna Pharmaceuticals (DRNA), ImmunoGen (IMGN), Y-mAbs Therapeutics (YMAB), Lexicon Pharmaceuticals (LXRX), AC Immune (ACIU), Principia Biopharma (PRNB) and Radius Health (RDUS).
Who are Catalyst Pharmaceuticals' key executives?
Catalyst Pharmaceuticals' management team includes the folowing people:
- Mr. Patrick J. McEnany, Co-Founder, Chairman, CEO & Pres (Age 71)
- Ms. Alicia Grande, VP, CFO & Treasurer (Age 47)
- Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 56)
- Mr. Brian Elsbernd, Sr. VP of Legal & Compliance (Age 54)
- Dr. Gary Ingenito, Chief Medical Officer (Age 62)
Who are Catalyst Pharmaceuticals' major shareholders?
Catalyst Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.09%), Vanguard Group Inc. (4.34%), Baker BROS. Advisors LP (2.82%), Sofinnova Ventures Inc (1.51%), JPMorgan Chase & Co. (0.96%) and JPMorgan Chase & Co. (0.96%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals.
Which major investors are selling Catalyst Pharmaceuticals stock?
CPRX stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, GSA Capital Partners LLP, AQR Capital Management LLC, TIAA CREF Investment Management LLC, Prudential Financial Inc. and Strs Ohio. View Insider Buying and Selling for Catalyst Pharmaceuticals.
Which major investors are buying Catalyst Pharmaceuticals stock?
CPRX stock was bought by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Dimensional Fund Advisors LP, BlackRock Inc., Vanguard Group Inc., Sofinnova Ventures Inc, JPMorgan Chase & Co., JPMorgan Chase & Co. and Bank of New York Mellon Corp. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals.
How do I buy shares of Catalyst Pharmaceuticals?
Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalyst Pharmaceuticals' stock price today?
One share of CPRX stock can currently be purchased for approximately $2.45.
How big of a company is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals has a market capitalization of $245.55 million. The biopharmaceutical company earns $-18,410,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Catalyst Pharmaceuticals employs 21 workers across the globe.
What is Catalyst Pharmaceuticals' official website?
How can I contact Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]
MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
